Previous treatment strategies have been hampered by the heterogeneity of the disease – escape of residual cells from radiotherapy, emergence of resistance to BRAF inhibition, etc – and a strategy which could target the tumor as a whole has eluded researchers. The gene discussed is BRAF; the disease is neoplasm.